MUFG Americas Holdings Corp lowered its stake in Shire PLC (NASDAQ:SHPG) by 21.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,087 shares of the biopharmaceutical company’s stock after selling 859 shares during the period. MUFG Americas Holdings Corp’s holdings in Shire were worth $560,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. Centaurus Financial Inc. bought a new stake in shares of Shire during the 2nd quarter valued at $102,000. Rehmann Capital Advisory Group boosted its holdings in shares of Shire by 226.9% during the 2nd quarter. Rehmann Capital Advisory Group now owns 680 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 472 shares in the last quarter. Valeo Financial Advisors LLC bought a new stake in shares of Shire during the 2nd quarter valued at $129,000. TRUE Private Wealth Advisors bought a new stake in shares of Shire during the 3rd quarter valued at $148,000. Finally, Whitener Capital Management Inc. bought a new stake in shares of Shire during the 3rd quarter valued at $156,000. Institutional investors and hedge funds own 20.49% of the company’s stock.
SHPG opened at $174.95 on Friday. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $53.41 billion, a PE ratio of 11.39, a P/E/G ratio of 1.58 and a beta of 1.01. Shire PLC has a 1 year low of $123.73 and a 1 year high of $182.47.
A number of brokerages have recently commented on SHPG. SunTrust Banks cut shares of Shire from a “buy” rating to a “hold” rating in a report on Tuesday, December 11th. ValuEngine upgraded shares of Shire from a “sell” rating to a “hold” rating in a report on Thursday, December 6th. B. Riley restated a “buy” rating on shares of Shire in a report on Tuesday, December 4th. BidaskClub cut shares of Shire from a “buy” rating to a “hold” rating in a report on Friday, November 30th. Finally, Zacks Investment Research restated a “hold” rating on shares of Shire in a report on Thursday, November 15th. Ten research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $201.11.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Further Reading: SEC Filing
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.